Verve Therapeutics News

Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery

TipRanksApr 8 06:25 ET

Verve Therapeutics Analyst Ratings

BenzingaApr 3 08:45 ET

Buy Rating Affirmed for Verve Therapeutics With Strategic Focus on Promising VERVE-102 Program

TipRanksApr 2 18:25 ET

Buy Rating Affirmed for Verve Therapeutics Amidst Promising Clinical Studies and Strategic Advancements

TipRanksFeb 28 15:25 ET

Verve Therapeutics Analyst Ratings

BenzingaFeb 28 10:46 ET

RBC Capital Sticks to Their Buy Rating for Verve Therapeutics (VERV)

TipRanksFeb 28 07:16 ET

RBC Capital Remains a Buy on Verve Therapeutics (VERV)

TipRanksNov 8, 2023 20:46 ET

Verve Therapeutics' Robust Financial Performance and Promising Future Prospects: A Buy Rating Justified

TipRanksNov 8, 2023 07:46 ET

Analysts' Top Healthcare Picks: Vigil Neuroscience Inc (VIGL), Verve Therapeutics (VERV)

TipRanksNov 7, 2023 10:00 ET

Strong Buy Rating for Verve Therapeutics: Influenced by Eli Lilly's Acquisition, Partnership Prospects, and Positive FDA Clearance

TipRanksOct 31, 2023 10:46 ET

Positive Prospects for Verve Therapeutics: FDA Approval, Innovative Treatment and Promising Preliminary Data Drive Buy Rating

TipRanksOct 24, 2023 06:40 ET

Analysts' Top Healthcare Picks: Verve Therapeutics (VERV), Immunovant (IMVT)

TipRanksOct 24, 2023 06:40 ET

Promising Future of Verve Therapeutics: A Comprehensive Analysis Supporting the Buy Rating

TipRanksOct 23, 2023 16:45 ET

Cantor Fitzgerald Reiterates Neutral on Verve Therapeutics, Maintains $22 Price Target

BenzingaSep 13, 2023 08:49 ET

Verve Therapeutics Analyst Ratings

BenzingaSep 13, 2023 08:26 ET

Cantor Fitzgerald Keeps Their Hold Rating on Verve Therapeutics (VERV)

TipRanksAug 30, 2023 02:05 ET

Cantor Fitzgerald Reiterates Neutral on Verve Therapeutics, Maintains $22 Price Target

BenzingaAug 29, 2023 12:04 ET

Verve Therapeutics Analyst Ratings

BenzingaAug 29, 2023 12:03 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Replimune Group (REPL) and Verve Therapeutics (VERV)

TipRanksAug 18, 2023 08:11 ET

Guggenheim Maintains Buy on Verve Therapeutics, Lowers Price Target to $55

BenzingaAug 15, 2023 11:09 ET